Allergan’s Aesthetic Device Lineup Gains Momentum In 2nd Quarter
This article was originally published in The Gray Sheet
Executive Summary
Allergan's core device sales soared 53.6% in the second quarter from a year ago to $197 million, building momentum for the firm's medical aesthetic products in "rapidly expanding markets," the firm reported Aug. 1
You may also be interested in...
Silicone Breast Implant Approvals Conditioned On Huge Postmarket Studies
FDA's Nov. 17 approval of silicone-gel breast implants comes with the requirement for one of the largest post-approval studies ever called for by the device center, according to CDRH Director Dan Schultz
Wrinkle-Filling Market-Leader Medicis Ready To Take On Juvederm
Medicis says the superior formulation of its Restylane dermal filler will enable it to fend off looming competition from a lower-priced offering by pharmaceutical powerhouse Allergan
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.